Muse & MSCs
The comparison is usually framed as old technology versus new. That is not what the science describes — and the real relationship is more interesting.
First, the relationship
Mesenchymal stem cells — MSCs — are the workhorses of regenerative medicine, taken from bone marrow, fat or umbilical cord. They have been studied for thirty years.
Muse cells are not an alternative to them. Muse cells are a subset of them: the one-to-three per cent of an MSC culture that has these particular properties. Every Muse cell preparation starts life as an MSC culture. The difference is whether a laboratory did the work to concentrate that fraction.
So the honest framing is not “which product is better.” It is “has this specific vial been through the separation step, or not?”
The comparison, honestly
Marketing comparisons tend to present every row of a table like this as a proven advantage. Most are laboratory observations. The right-hand column says what kind of evidence sits behind each one.
| Property | What is different | How solid is it? |
|---|---|---|
| Getting to the injury | Muse cells follow a chemical distress signal to damaged tissue. Ordinary MSCs, given by drip, largely lodge in the lungs and mostly disappear within a day. | Well demonstrated in animals, with proper controls. Never measured in a human patient — no study has tracked where the cells went. |
| Surviving stress | Muse cells tolerate conditions that kill ordinary cells. This is the property they are named for and the basis of how they are isolated. | Solid and independently replicated. |
| Range of tissue types | Muse cells produce markers of all three major tissue families in the laboratory; ordinary MSCs have a narrower range. | Established in the laboratory. Whether it translates into tissue repair in patients is unresolved. |
| Immune tolerance | Muse cells carry HLA-G, a natural tolerance signal, at far higher levels than ordinary MSCs. | The molecule is clearly present. But it fades within about two weeks, and the blood tests that would confirm real tolerance were never run in the human studies. |
| Tumour risk | Neither forms tumours. Muse cells do not carry the runaway growth risk of embryonic or reprogrammed stem cells. | For MSCs this rests on thousands of patients across dozens of trials. For Muse cells it rests on about 67 patients and a narrow set of animal tests. Same answer, very different amounts of evidence. |
| Better patient outcomes | This is the claim the whole category is sold on. | Never tested. No trial has ever compared Muse cells against ordinary MSCs in patients, for any condition. |
The part most comparisons leave out
Muse cells are frequently presented as the advanced option and MSCs as the outgoing one. On the measures regulators use, it is the other way round.
Ordinary MSCs
Roughly 1,850 registered clinical trials, 126 of them at the largest late stage. Eleven products have been approved by regulators across seven countries — for graft-versus-host disease, spinal cord injury, heart attack, cartilage damage, Crohn's fistulas and more.
Muse cells
Six published studies, about 67 patients, one with a comparison group. No approvals anywhere in the world. The company that ran every one of those studies discontinued the programme in February 2023 — a commercial decision, not a safety withdrawal, but the follow-up trials were never run.
To be fair to both sides
MSC results are not uniformly impressive either — several large, well-run MSC trials have missed their targets, and one European approval was withdrawn. The field has real problems. But a treatment with disappointing large trials is still further along than one that has not run them.
So where does that leave the choice
Both are legitimate decisions — but they optimise for different things. The honest way to choose is to know which kind of buyer you are before you talk to anyone selling either.
Choose MSC therapy if…
You're paying for thirty years of clinical experience, more than a thousand completed trials, and — in a small number of specific conditions, like graft-versus-host disease — actual regulatory approvals. The mechanism is well-understood even where results are mixed, and a large body of evidence stands behind its safety in thousands of patients.
Choose a Muse preparation if…
Your priority is cells that can actually reach the injury instead of lodging in the lungs, delivered without donor matching or immunosuppressants — and you accept that human evidence is early-stage, small, and unapproved, because for your condition no cell therapy of any kind is approved. You'd be choosing based on mechanism, not on proven superior outcomes.
The one question that changes the decision
Whichever side you lean, the honest state of the evidence is the same: no head-to-head trial has ever been run. If a seller on either side tells you the science has settled this, ask them which study. If they can't name one, they've answered a different question than the one you asked.
So where does that leave it
Muse cells have one property ordinary stem cells clearly lack — they can get past the lungs and reach an injury under their own direction. That is real, and it addresses a genuine weakness in conventional stem cell therapy.
What has not been shown is that this translates into patients doing better. Turning that mechanism into an answer would take a properly sized trial with treatment benefit as the main question, human scans tracking where the cells actually go, and one direct comparison against ordinary MSCs. None of those has been done.
Until then, “Muse cells are better” is a well-motivated hypothesis. Anyone presenting it as a settled finding is going beyond the evidence — and you are entitled to ask them which study they are relying on.
